IQWiG assessment of Sovaldi for Hepatitis C - Gilead Sciences
IQWiG (The German Institute for Quality & Efficiency in Healthcare) found that the submission made by Gilead Sciences for Solvadi (sofosbuvir) for treatment of Hepartitis C provided added benefit for non pre-treated patients infected with Genotype 2 virus however the extent cannot be quantified. There was no suitable data submitted for patients infected with the other virus types. There were no adequate analyses for infection for Genotype 1 and types 3 to 6 and HIV co infection. Gilead had cited the FISSION study but IQWiG assessments of that study found the risk of bias as high.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.